Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Publication year range
1.
Int J Mol Sci ; 19(4)2018 Apr 11.
Article in English | MEDLINE | ID: mdl-29641465

ABSTRACT

Despite the development of numerous therapeutics targeting the epithelial growth factor receptor (EGFR) for non-small cell lung carcinoma (NSCLC), the application of these drugs is limited because of drug resistance. Here, we investigated the antitumor effect of calcium-mediated degradation of EGFR pathway-associated proteins on NSCLC. First, lactate calcium salt (LCS) was utilized for calcium supplementation. Src, α-tubulin and EGFR levels were measured after LSC treatment, and the proteins were visualized by immunocytochemistry. Calpeptin was used to confirm the calcium-mediated effect of LCS on NSCLC. Nuclear expression of c-Myc and cyclin D1 was determined to understand the underlying mechanism of signal inhibition following EGFR and Src destabilization. The colony formation assay and a xenograft animal model were used to confirm the in vitro and in vivo antitumor effects, respectively. LCS supplementation reduced Src and α-tubulin expression in NSCLC cells. EGFR was destabilized because of proteolysis of Src and α-tubulin. c-Myc and cyclin D1 expression levels were also reduced following the decrease in the transcriptional co-activation of EGFR and Src. Clonogenic ability and tumor growth were significantly inhibited by LSC treatment-induced EGFR destabilization. These results suggest that other than specifically targeting EGFR, proteolysis of associated molecules such as Src or α-tubulin may effectively exert an antitumor effect on NSCLC via EGFR destabilization. Therefore, LCS is expected to be a good candidate for developing novel anti-NSCLC therapeutics overcoming chemoresistance.


Subject(s)
Antineoplastic Agents/pharmacology , Calcium Compounds/pharmacology , Carcinoma, Non-Small-Cell Lung/drug therapy , ErbB Receptors/metabolism , Lactates/pharmacology , Lung Neoplasms/drug therapy , Proteolysis , Animals , Antineoplastic Agents/therapeutic use , Calcium Compounds/therapeutic use , Cell Line, Tumor , Cyclin D1/metabolism , Dipeptides/metabolism , Female , Humans , Lactates/therapeutic use , Mice , Mice, Inbred BALB C , Mice, Nude , Protein Stability/drug effects , Tubulin/metabolism , src-Family Kinases/metabolism
2.
Anticancer Res ; 37(6): 2959-2964, 2017 06.
Article in English | MEDLINE | ID: mdl-28551633

ABSTRACT

BACKGROUND/AIM: 5-Fluorouracil (5-FU) over-use has led to an urgent need for alternative treatment regimens, such as a lower concentration of the drug because of its toxic effects. The aim of this study was to investigate the possibility of improving the antitumor effect of 5-FU without toxicity by targeting primary colorectal cancer (CRC) with sustained calcium supplementation. MATERIALS AND METHODS: The viability of CRC cells was determined after treatment of 5-FU, lactate calcium salt (CaLac), or the combination of te two. Western blot analysis for the focal adhesion kinase (FAK) signaling cascade was performed to investigate the underlying mechanism. A xenograft model was established to evaluate antitumor efficacy of each treatment, and the necrotic effect was also observed in tumor tissues. RESULTS: By the combined treatment, proteolysis of FAK signaling cascade, was mediated by sustained calcium supplementation resulting in further decrease in the clonogenicity of CRC cells. The in vivo anticancer efficacy including tumor necrosis was significantly increased by the combination treatment compared to single treatment of with 5-FU. CONCLUSION: Sustained calcium supplementation was able to enhance the potency of 5-FU targeting the primary CRC.


Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Calcium Compounds/therapeutic use , Colorectal Neoplasms/drug therapy , Fluorouracil/therapeutic use , Lactates/therapeutic use , Animals , Antimetabolites, Antineoplastic/pharmacology , Calcium Compounds/pharmacology , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/pathology , Fluorouracil/pharmacology , Focal Adhesion Kinase 1/antagonists & inhibitors , Focal Adhesion Kinase 1/metabolism , HCT116 Cells , HT29 Cells , Humans , Lactates/pharmacology , Mice, Inbred BALB C , Mice, Nude , Tumor Burden/drug effects , Xenograft Model Antitumor Assays
3.
Oncotarget ; 8(24): 39367-39381, 2017 Jun 13.
Article in English | MEDLINE | ID: mdl-28455965

ABSTRACT

Individualizing adjuvant chemotherapy is important in patients with advanced colorectal cancers (CRCs), and the ability to identify molecular subtypes predictive of good prognosis for stage III CRCs after adjuvant chemotherapy could be highly beneficial. We performed microarray-based gene expression analysis on 101 fresh-frozen primary samples from patients with stage III CRCs treated with FOLFOX adjuvant chemotherapy and 35 matched non-neoplastic mucosal tissues. CRC samples were classified into four molecular subtypes using nonnegative matrix factorization, and for comparison, we also grouped CRC samples using the proposed consensus molecular subtypes (CMSs). Of the 101 cases, 80 were classified into a CMS group, which shows a 79% correlation between the CMS classification and our four molecular subtypes. We found that two of our subtypes showed significantly higher disease-free survival and overall survival than the others. Group 2, in particular, which showed no disease recurrence or death, was characterized by high microsatellite instability (MSI-H, 6/21), abundant mucin production (12/21), and right-sided location (12/21); this group strongly correlated with CMS1 (microsatellite instability immune type). We further identified the molecular characteristics of each group and selected 10 potential biomarker genes from each. When these were compared to the previously reported molecular classifier genes, we found that 31 out of 40 selected genes were matched with those previously reported. Our findings indicate that molecular classification can reveal specific molecular subtypes correlating with clinicopathologic features of CRCs and can have predictive value for the prognosis for stage III CRCs with FOLFOX adjuvant chemotherapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/mortality , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Biomarkers, Tumor , Chemotherapy, Adjuvant , Cluster Analysis , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/genetics , Computational Biology , Female , Fluorouracil/adverse effects , Fluorouracil/therapeutic use , Gene Expression Profiling , Humans , Leucovorin/adverse effects , Leucovorin/therapeutic use , Male , Middle Aged , Neoplasm Staging , Organoplatinum Compounds/adverse effects , Organoplatinum Compounds/therapeutic use , Prognosis , Survival Analysis , Transcriptome , Treatment Outcome
4.
Anticancer Res ; 37(1): 103-114, 2017 01.
Article in English | MEDLINE | ID: mdl-28011480

ABSTRACT

AIM: To investigate the possibility of enhancing an anti-metastatic effect of 5-fluorouracil (5-FU) on colorectal cancer (CRC) cells by combining it with continuous calcium supplementation. MATERIALS AND METHODS: Optimal doses of 5-FU with/without lactate salt (CaLa) were determined via clonogenicity and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays using human CRC cells cultured on normal or low-attachment plates. Invasion and migration assays confirmed the enhanced anti-metastatic effect of combining 5-FU and CaLa. Western blot analysis for elements of the focal adhesion kinase (FAK) signaling cascade and epithelial-mesenchymal transition (EMT) markers was used to investigate the underlying mechanism. RESULTS: 5-FU (2.5 µM) had no antitumor activity against unanchored CRC cells, while it significantly suppressed anchorage-dependent cell proliferation. In contrast, treatment with CaLa (2.5 mM), alone and in combination with 5-FU, exerted antitumor activity against both anchored and unanchored CRC cells via calcium-mediated FAK proteolysis and inhibition of EMT markers, such as vimentin and SNAIL. CONCLUSION: Calcium supplementation represents a method of enhancing the potency of existing antitumor agents such as 5-FU, augmenting their clinical effectiveness.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Calcium Compounds/pharmacology , Cell Movement/drug effects , Colorectal Neoplasms/drug therapy , Fluorouracil/pharmacology , Focal Adhesion Kinase 1/metabolism , Lactates/pharmacology , Biomarkers, Tumor/metabolism , Cell Death/drug effects , Cell Proliferation/drug effects , Colorectal Neoplasms/enzymology , Colorectal Neoplasms/pathology , Dose-Response Relationship, Drug , Drug Synergism , Epithelial-Mesenchymal Transition/drug effects , HCT116 Cells , HT29 Cells , Humans , Neoplasm Invasiveness , Neoplasm Metastasis , Proteolysis , Signal Transduction/drug effects , Time Factors
5.
Prep Biochem Biotechnol ; 37(3): 239-46, 2007.
Article in English | MEDLINE | ID: mdl-17516253

ABSTRACT

Buckwheat (Fagopyrum esculentum Moench.) is a potentially important source of rutin, a natural flavonoid with antihyperglycemic, antihypertensive, and antioxidative properties. To examine in vitro production of rutin, we established a hairy root culture of buckwheat by infecting leaf explants with Agrobacterium rhizogenes R1000, and tested the growth conditions and rutin production rates of these cultures. Ten hairy root clones were established; their growth and rutin production rates ranged from 233 to 312 (mg dry wt per 30 mL flask, and 0.8 to 1.2 (mg/g dry wt), respectively. Clone H8, which had high growth and rutin production rates (312 mg dry wt per 30 mL flask and 1.2 mg/g dry wt, respectively), was selected for further experiments. H8 showed maximal growth and rutin content at 30 days in culture in MS medium. Of four tested culture media, half-strength MS medium was found to induce the highest levels of growth (378 mg dry wt per 30 mL flask) and rutin production (1.4 mg/g dry wt) by clone H8. In contrast, supplementation with auxins (0.1-1 mg/l IAA, IBA and NAA) increased the growth rate, but had no significant effect on rutin production by H8. Collectively, these findings indicate that hairy root cultures of buckwheat culture could be a valuable alternative approach for rutin production.


Subject(s)
Fagopyrum/growth & development , Plant Roots/growth & development , Plants, Genetically Modified/metabolism , Rutin/biosynthesis , Rutin/isolation & purification , Tissue Culture Techniques , Chromatography, High Pressure Liquid/methods , Culture Media/chemistry , Plant Extracts/chemistry , Plant Roots/chemistry , Plants, Medicinal/chemistry , Rhizobium/enzymology , Rutin/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL